Clinical Trials · NCT01021527
A Study to Assess the Effects of Exenatide on Insulin Secretion Rates Using a Graded Infusion of Intravenous Glucose (0000-099)(COMPLETED)
- Phase
- Phase 1
- Recruitment status
- Completed
- Sponsor
- Merck Sharp & Dohme LLC
- Enrollment
- 12
- Start date
- Feb 2008
- Locations
- See registry
- Primary endpoint
- beta-cell glucose sensitivity (slope of the relationship between insulin secretion rate and glucose)